Zacks Research Issues Negative Outlook for Chemours Earnings

The Chemours Company (NYSE:CC - Free Report) - Zacks Research lowered their FY2024 earnings per share (EPS) estimates for Chemours in a research report issued on Tuesday, January 14th. Zacks Research analyst R. Department now expects that the specialty chemicals company will post earnings per share of $1.20 for the year, down from their prior forecast of $1.28. The consensus estimate for Chemours' current full-year earnings is $1.21 per share. Zacks Research also issued estimates for Chemours' Q1 2026 earnings at $0.61 EPS.

Several other analysts have also recently weighed in on the stock. Morgan Stanley dropped their price objective on shares of Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a research note on Monday. Mizuho reduced their price target on Chemours from $22.00 to $21.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $25.00 price objective on shares of Chemours in a report on Thursday, December 12th. BMO Capital Markets increased their target price on Chemours from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, October 7th. Finally, The Goldman Sachs Group dropped their price target on Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a research note on Tuesday, January 7th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $23.75.

Chemours Stock Performance

Shares of CC traded up $0.32 during midday trading on Friday, reaching $19.41. 1,414,619 shares of the stock were exchanged, compared to its average volume of 1,613,529. The company has a quick ratio of 0.92, a current ratio of 1.73 and a debt-to-equity ratio of 6.05. The stock's 50 day simple moving average is $19.13 and its 200 day simple moving average is $19.77. Chemours has a twelve month low of $15.10 and a twelve month high of $32.48. The company has a market cap of $2.90 billion, a P/E ratio of 38.82 and a beta of 1.83.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, topping analysts' consensus estimates of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. During the same quarter last year, the company earned $0.64 earnings per share. The firm's quarterly revenue was up .9% compared to the same quarter last year.

Chemours Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Friday, November 15th were paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 5.15%. The ex-dividend date was Friday, November 15th. Chemours's payout ratio is 200.00%.

Insider Transactions at Chemours

In other news, SVP Alvenia Scarborough sold 7,500 shares of the company's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the completion of the transaction, the senior vice president now directly owns 16,645 shares in the company, valued at approximately $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.47% of the company's stock.

Institutional Investors Weigh In On Chemours

A number of hedge funds and other institutional investors have recently bought and sold shares of CC. Matrix Trust Co acquired a new stake in shares of Chemours during the third quarter valued at about $25,000. Blue Trust Inc. raised its holdings in Chemours by 166.9% in the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after buying an additional 731 shares during the last quarter. GAMMA Investing LLC boosted its position in Chemours by 99.7% during the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after buying an additional 765 shares during the period. Truvestments Capital LLC bought a new stake in Chemours during the 3rd quarter worth approximately $35,000. Finally, Brooklyn Investment Group bought a new stake in Chemours during the 3rd quarter worth approximately $37,000. Institutional investors own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.